• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

国际纤维性骨发育不良进展性(FOP)协会全球注册中心的自我报告的基线表型。

Self-reported baseline phenotypes from the International Fibrodysplasia Ossificans Progressiva (FOP) Association Global Registry.

机构信息

Department of Medicine, Mayo Clinic School of Medicine, Mayo Clinic, Rochester, MN, United States.

BioSAS Consulting, Inc., Wellesley, MA, United States.

出版信息

Bone. 2020 May;134:115274. doi: 10.1016/j.bone.2020.115274. Epub 2020 Feb 13.

DOI:10.1016/j.bone.2020.115274
PMID:32062004
Abstract

A global, patient-reported registry has been established to characterize the course of disease and track clinical outcomes in patients with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic condition of progressive heterotopic ossification (HO) that results in ankylosis of joints and renders most affected individuals immobile by the second decade of life. Here, we present baseline phenotypes on 299 patients (median age 21 years; range 0.1 to 78 years) from 54 countries based on aggregate data from the International FOP Association (IFOPA) Global Registry (the "FOP Registry"). The mean current age of the patients is 23.7 years (range, 0.1 to 78 years). Baseline characteristics are presented for FOP diagnosis, HO, flare-ups and precedent events, system-based prevalent symptomatology, encounters with medical and dental care providers, Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Scale scores, physical function, as well as the use of aids, assistive devices, and adaptations. Correlations of PROMIS Global Health scores with HO burden and physical function are calculated. Associations of joint mobility with PROMIS Global Health scores, physical function, and use of aids, assistive devices, and adaptations are summarized. Overall, the FOP Registry database contains a broad sample of the global FOP patient population, providing a useful tool for expanding knowledge of FOP, designing clinical trials and facilitating evidence-based decisions about the optimal monitoring and management of affected individuals.

摘要

一个全球性的、基于患者报告的注册系统已经建立,旨在描述成骨不全性纤维发育不良(FOP)患者的疾病进程,并跟踪其临床结局。FOP 是一种罕见的遗传性疾病,其特征为进行性异位骨化(HO),导致关节强直,大多数受影响个体在生命的第二个十年就丧失活动能力。在此,我们根据国际 FOP 协会(IFOPA)全球注册中心(“FOP 注册中心”)的汇总数据,介绍了来自 54 个国家的 299 名患者(中位年龄 21 岁;年龄范围 0.1 至 78 岁)的基线表型。这些患者的平均当前年龄为 23.7 岁(年龄范围 0.1 至 78 岁)。介绍了 FOP 诊断、HO、发作和前期事件、基于系统的普遍症状、与医疗和牙科保健提供者的接触、患者报告的测量信息系统(PROMIS)全球健康量表评分、身体功能以及辅助器具、辅助设备和适应的使用情况等方面的基线特征。计算了 PROMIS 全球健康评分与 HO 负担和身体功能的相关性。总结了关节活动度与 PROMIS 全球健康评分、身体功能以及辅助器具、辅助设备和适应的使用之间的关联。总体而言,FOP 注册中心数据库包含了全球 FOP 患者群体的广泛样本,为扩展对 FOP 的认识、设计临床试验以及促进有关受影响个体的最佳监测和管理的循证决策提供了有用的工具。

相似文献

1
Self-reported baseline phenotypes from the International Fibrodysplasia Ossificans Progressiva (FOP) Association Global Registry.国际纤维性骨发育不良进展性(FOP)协会全球注册中心的自我报告的基线表型。
Bone. 2020 May;134:115274. doi: 10.1016/j.bone.2020.115274. Epub 2020 Feb 13.
2
The FOP Connection Registry: Design of an international patient-sponsored registry for Fibrodysplasia Ossificans Progressiva.FOP 连接注册表:国际患者赞助的纤维性骨发育不良进展性疾病注册表设计。
Bone. 2018 Apr;109:285-290. doi: 10.1016/j.bone.2017.08.032. Epub 2017 Sep 1.
3
Natural history of fibrodysplasia ossificans progressiva: cross-sectional analysis of annotated baseline phenotypes.纤维性骨发育不良进展性的自然史:注释基线表型的横断面分析。
Orphanet J Rare Dis. 2019 May 3;14(1):98. doi: 10.1186/s13023-019-1068-7.
4
Most Fractures Treated Nonoperatively in Individuals With Fibrodysplasia Ossificans Progressiva Heal With a Paucity of Flareups, Heterotopic Ossification, and Loss of Mobility.大多数纤维性骨发育不良性骨化性肌炎患者的骨折经非手术治疗后愈合,且很少出现发作、异位骨化和活动度丧失。
Clin Orthop Relat Res. 2023 Dec 1;481(12):2447-2458. doi: 10.1097/CORR.0000000000002672. Epub 2023 May 8.
5
Fibrodysplasia Ossificans Progressiva进行性骨化性纤维发育不良
6
Skeletal malformations and developmental arthropathy in individuals who have fibrodysplasia ossificans progressiva.纤维性骨发育不良所致骨化性肌炎患者的骨骼畸形和发育性关节病。
Bone. 2020 Jan;130:115116. doi: 10.1016/j.bone.2019.115116. Epub 2019 Oct 23.
7
Social and clinical impact of COVID-19 on patients with fibrodysplasia ossificans progressiva.COVID-19 对进行性骨化性纤维发育不良患者的社会和临床影响。
Orphanet J Rare Dis. 2022 Mar 4;17(1):107. doi: 10.1186/s13023-022-02246-4.
8
Prevalence of fibrodysplasia ossificans progressiva (FOP) in the United States: estimate from three treatment centers and a patient organization.纤维性骨发育不良伴进行性骨化(FOP)在美国的流行率:来自三个治疗中心和一个患者组织的估计。
Orphanet J Rare Dis. 2021 Aug 5;16(1):350. doi: 10.1186/s13023-021-01983-2.
9
A cumulative analogue joint involvement scale (CAJIS) for fibrodysplasia ossificans progressiva (FOP).进行性骨化性纤维发育不良(FOP)的累积模拟关节受累量表(CAJIS)
Bone. 2017 Aug;101:123-128. doi: 10.1016/j.bone.2017.04.015. Epub 2017 Apr 29.
10
Characterization of flare-ups and impact of garetosmab in adults with fibrodysplasia ossificans progressiva: a post hoc analysis of the randomized, double-blind, placebo-controlled LUMINA-1 trial.成纤维细胞性骨化发育不良成人患者flare-ups 的特征及 garetosmab 的影响:LUMINA-1 试验的一项随机、双盲、安慰剂对照的事后分析。
J Bone Miner Res. 2024 Sep 26;39(10):1486-1492. doi: 10.1093/jbmr/zjae140.

引用本文的文献

1
A systematic literature review of the impact and measurement of mobility impairment in rare bone diseases.罕见骨病中活动能力障碍的影响及测量的系统文献综述。
Ther Adv Musculoskelet Dis. 2025 Aug 21;17:1759720X251369963. doi: 10.1177/1759720X251369963. eCollection 2025.
2
Assessing the economic burden and health-related quality of life in chinese patients with fibrodysplasia ossificans progressiva: a questionnaire survey analysis.评估中国进行性骨化性纤维发育不良患者的经济负担和健康相关生活质量:一项问卷调查分析。
Orphanet J Rare Dis. 2025 Aug 7;20(1):411. doi: 10.1186/s13023-025-03884-0.
3
Respiratory oscillometry in individuals with fibrodysplasia ossificans progressiva.
进行性骨化性纤维发育不良患者的呼吸振荡法
Orphanet J Rare Dis. 2025 Jul 1;20(1):323. doi: 10.1186/s13023-025-03846-6.
4
Understanding the clinical morbidity and mortality of fibrodysplasia ossificans progressiva: a systematic literature review.进行性骨化性纤维发育不良的临床发病率和死亡率:一项系统文献综述
Orphanet J Rare Dis. 2025 May 31;20(1):262. doi: 10.1186/s13023-025-03763-8.
5
Hearing loss predictive model in fibrodysplasia ossificans progressiva from a national referral center: developing an hearing loss predictive model.来自国家转诊中心的进行性骨化性纤维发育不良听力损失预测模型:建立听力损失预测模型。
JBMR Plus. 2025 Feb 14;9(4):ziaf029. doi: 10.1093/jbmrpl/ziaf029. eCollection 2025 Apr.
6
Early Detection for Better Patient Outcome: A Case Report on Two Patients Presenting With Fibrodysplasia Ossificans Progressiva at Tikur Anbessa Specialized Hospital, Ethiopia.早期检测以改善患者预后:埃塞俄比亚提库尔安贝萨专科医院两例进行性骨化性纤维发育不良患者的病例报告
Case Rep Orthop. 2025 Jan 29;2025:2161762. doi: 10.1155/cro/2161762. eCollection 2025.
7
Tracheostomy for the pediatric patient with fibrodysplasia ossificans progressiva: a case report.小儿进行性骨化性纤维发育不良患者的气管切开术:一例报告
Surg Case Rep. 2024 Mar 15;10(1):61. doi: 10.1186/s40792-024-01864-3.
8
Sex as a Critical Variable in Basic and Pre-Clinical Studies of Fibrodysplasia Ossificans Progressiva.性别的基础和临床前研究中的纤维发育不良性骨化进展的关键变量。
Biomolecules. 2024 Feb 1;14(2):177. doi: 10.3390/biom14020177.
9
Diminished muscle integrity in patients with fibrodysplasia ossificans progressiva assessed with at-home electrical impedance myography.应用家庭式电阻抗肌图评估进行性骨化性纤维发育不良患者的肌肉完整性受损。
Sci Rep. 2022 Dec 3;12(1):20908. doi: 10.1038/s41598-022-25610-7.
10
Current challenges and opportunities in the care of patients with fibrodysplasia ossificans progressiva (FOP): an international, multi-stakeholder perspective.纤维性骨发育不良进展性(FOP)患者护理方面的当前挑战与机遇:国际多利益相关方视角。
Orphanet J Rare Dis. 2022 Apr 18;17(1):168. doi: 10.1186/s13023-022-02224-w.